The Mucosal Adjuvant Cholera Toxin B Instructs Non-Mucosal Dendritic Cells to Promote IgA Production Via Retinoic Acid and TGF-β

Anouk K. Gloudemans, Maud Plantinga, Martin Guilliams, Monique A. Willart, Arifa Ozir-Fazalalikhan, Alwin van der Ham, Louis Boon, Nicola L. Harris, Hamida Hammad, Henk C. Hoogsteden, Maria Yazdanbakhsh, Rudi W. Hendriks, Bart N. Lambrecht, Hermelijn H. Smits

Research output: Contribution to journalArticleResearchpeer-review

29 Citations (Scopus)

Abstract

It is currently unknown how mucosal adjuvants cause induction of secretory immunoglobulin A (IgA), and how T cell-dependent (TD) or -independent (TI) pathways might be involved. Mucosal dendritic cells (DCs) are the primary antigen presenting cells driving TI IgA synthesis, by producing a proliferation-inducing ligand (APRIL), B cell activating factor (BAFF), Retinoic Acid (RA), TGF-β or nitric oxide (NO). We hypothesized that the mucosal adjuvant Cholera Toxin subunit B (CTB) could imprint non-mucosal DCs to induce IgA synthesis, and studied the mechanism of its induction. In vitro, CTB-treated bone marrow derived DCs primed for IgA production by B cells without the help of T cells, yet required co-signaling by different Toll-like receptor (TLR) ligands acting via the MyD88 pathway. CTB-DC induced IgA production was blocked in vitro or in vivo when RA receptor antagonist, TGF-β signaling inhibitor or neutralizing anti-TGF-β was added, demonstrating the involvement of RA and TGF-β in promoting IgA responses. There was no major involvement for BAFF, APRIL or NO. This study highlights that synergism between CTB and MyD88-dependent TLR signals selectively imprints a TI IgA-inducing capacity in non-mucosal DCs, explaining how CTB acts as an IgA promoting adjuvant.

Original languageEnglish
Article numbere59822
Number of pages10
JournalPLoS ONE
Volume8
Issue number3
DOIs
Publication statusPublished - 20 Mar 2013
Externally publishedYes

Cite this